UBS put out a report on genetics and included a list of companies involved. Ex-ILMN and TMO, PACB is the only way to directly go after sequencing.
Despite the fact the current biotech shake-out has nothing to do with PACB, I believe Mr. Illogical Market will not be able to make that distinction. I think we see minimum mid 4's and then it will be time to make another decision. If only the impatient could have waited for better prices but, boys will be boys and impatience will no doubt be costly. What's new?
"We have seen great demand for SMRT Sequencing in Korea and abroad, and are now running more SMRT Cells than flow cells or chips from any other sequencing platform," said Gun-Eui Lee, Chief Technology Officer of DNA Link. "Once customers experience the benefits of PacBio long reads, they especially prefer this technology for de novo sequencing."
couple of things;
1) there is a group who is using special library prep with ilmn machine and they are getting longer read lengths, this was reported a couple of months ago and might be having an effect on pacb.
2) oxford is nowhere close to having a commercial product, a lot of hype with oxford but oxford yet to produce one commercial device, ilmn has 10k machines sold and pacb a few
dozen sold to date. ilmn had a minority stake in oxford and they sold it, you think they are worried about oxford? Craig Venter is buying ilmn machines, you think he doesn't know the tech better than you and me? he is the 'godfather" of sequencing.
3) pacb has its place in the market though, ever since Roche got snubbed by ilmn two years ago when they tried to buy them, the only other game in town is pacb, and having Roche as a big bro is very resourceful and helpful in designing and developing future pacb sequencers.
4)Read lengths are not the only advantage pacb has on ilmn, the fact that they do single molecule sequencing gives them an edge, whereas others like ilmn do "average" sequencing.
the market is totally dominated by ilmn they have a 70% install base and 90% of sequencing data is generated by their machines. However, the market is so large that there is room for more players, like pacb. they just need to continue to innovate and bring costs down.
just my two cents.
Posted on March 19, 2015 by Alex
"We’re already seeing sessions on long-read sequencing on the agendas of other upcoming conferences, leading to our theory that 2015 will go down in sequencing history as the Year of Long Reads. It’s no wonder demand for this kind of data is soaring: after years of using short-read sequencers to analyze genomes, scientists are just now realizing how much information about structural variants, haplotype phasing, and other long-range, clinically relevant elements is inaccessible with short reads alone."
"There are a couple of different approaches to long-read data. Single-molecule sequencing platforms, like those available through PacBio and Oxford Nanopore Technologies, generate truly long reads on their own. Users of both platforms have presented individual reads running well into tens of kilobases, a far cry from the few hundred bases we’re used to from Illumina and Ion Torrent sequencers. Assembling those long reads can lead to megabase-plus contigs.
Just goes to show how much faith the insiders in the know have on what's going on that we don't. 400,000 AT $5.72 IS $2,288,000. And Barnes 250,000 at $5.72 is 1,430,000. That's alot of money. ALWAYS follow the insiders.
Sentiment: Strong Buy
Posted today on Nasdaq website:
Michael Hunkapillar, CEO, 400K shares at 5.72 (closing price 3/16)
Sandra Barnes, CFO, 250K shares at 5.72 (closing price 3/16)
Neither of these individuals receives a salary so these option grants appear to be a bullish sign on where this company is headed in the long run.
Looking forward to the next chemistry release in the upcoming months.
Sentiment: Strong Buy
I also loaded up more than I should, but, just cannot resist it at this low price. I watched the AGBT webcast from the PacBio blog and am very impress by the progress of the SMRT technology. Craig Venter's first appearance to the AGBT and his endorsement to the PacBio technology ensure me that PacBio's future is bright and the long term investment is worth the bet.
feedback i got from an attendee indicates that the people who went to their presentation are largely disappointed. There was no new news, and there is the belief that creating improvements on their technology using a single molecule may be technologically challenging (READ: not possible) using the current PacBio technology.
there are two threats as well to their long read length advantage. One is from the synthetic long reads via the 10x Genomics, which will have a real impact on PacBio. The other is from Oxford who has been improving and if the continue to trend as they have will also be a very real threat to not only PAcBio but to ILMN as well.
So right now there is no compelling reason to buy Pacbio. There is no diagnostic machine on the near term horizon, if ever. Also, given the 10X device it will make sales harder for Pacbio as people will want to sit on their hands and see how that technology plays out before making a 700K commitment to the RS device. So while I was very optimistic a month or so ago, now with this new information i lean towards pessimism.
I think long term this is a good stock to own, but a lot of people were probably disappointed that they were a Gold Sponsor at AGBT and put out nothing of substance there. In fact the privately-held company 10X essentially "scooped" them.